Mild cognitive impairment: To diagnose or not to diagnose

Kate N Wang1,2,3, Amy T Page2,3,4, Christopher D Etherton-Beer5

  • 1School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.

Insights

Mild cognitive impairment (MCI) involves noticeable cognitive decline in older adults but doesn't meet dementia criteria. Evidence for diagnosis benefits and effective interventions remains limited, with many individuals improving or not progressing to dementia.

Area of Science:

  • Gerontology
  • Neurology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is characterized by a noticeable decline in cognitive function in older adults.
  • Individuals with MCI do not meet the diagnostic criteria for dementia, and its clinical status is debated.
  • A significant portion of individuals with MCI experience improvement, and most do not progress to dementia.

Purpose of the Study:

  • To review the current understanding of mild cognitive impairment (MCI) in older adults.
  • To evaluate the diagnostic and prognostic value of MCI.
  • To assess the effectiveness of potential interventions for MCI.

Main Methods:

  • Literature review of studies on mild cognitive impairment.
  • Analysis of diagnostic criteria and prognostic indicators for MCI.
  • Evaluation of intervention strategies, including comorbidity management and exercise.

Main Results:

  • The prognostic value of MCI is uncertain, with many individuals showing spontaneous improvement.
  • Effective interventions for MCI are not well-established, with limited supporting evidence.
  • Managing co-morbidities and physical activity are suggested as primary management strategies.

Conclusions:

  • The benefit of diagnosing mild cognitive impairment (MCI) remains unclear due to limited evidence for effective treatments and uncertain prognosis.
  • Further research is needed to clarify the clinical significance and management of MCI.
  • Focusing on managing co-morbidities and promoting exercise may be the most beneficial approach for individuals with MCI.

Related Concept Videos

Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
318
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
285
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
309
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
500